A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

Must have received: standard therapy

at least 2 distinct lesions that have either failed or recurred despite treatment with 1 previous standard therapy

Cannot have received: Total Skin Electron Beam Therapy

In the past 12 weeks: Total Skin Electron Beam Therapy (TSEBT)

Cannot have received: topical imiquimod

In the past 8 weeks: topical imiquimod

Cannot have received: topical corticosteroids

In the past 4 weeks: topical corticosteroids

Cannot have received: topical chemotherapy

In the past 4 weeks: topical chemotherapy

Cannot have received: topical retinoids

In the past 4 weeks: topical retinoids

Cannot have received: local radiation therapy

In the past 4 weeks: local radiation therapy

Cannot have received: UVB therapy

In the past 4 weeks: UVB therapy

Cannot have received: PUVA

In the past 4 weeks: PUVA

Cannot have received: photopheresis

In the past 4 weeks: photopheresis

Cannot have received: systemic retinoids

In the past 4 weeks: systemic retinoids

Cannot have received: systemic corticosteroids

In the past 4 weeks: systemic corticosteroids

Cannot have received: interferon inducers

In the past 4 weeks: interferon inducers

Cannot have received: systemic chemotherapeutic agents

In the past 4 weeks: systemic chemotherapeutic agents